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Table 1. Performance of albumin levels and platelet count alone and in combination as predictors of death or severe complications according to the CUPIC Study
data.
Death or severe 
complications
All patients 
(n = 429) n
No 
(n = 400)
Yes 
(n = 30)
Accuracy 
(%)
Sensitivity Specificity
(%) (%)
PPV 
(%)
NPV 
(%)
LR+ LR-
Albumin (n = 74) ≥35 367 354 13
87 57 89 27 97 5.02 0.49
<35 62 45 17
Platelet count (n = 129) >100,000 326 314 12
77 60 79 19 96 2.82 0.51
≤100,000 103 85 18
Albumin <35 g/L and 
platelet count 
≤100,000/mm3
No 395 380 15
92 50 95 44 96 10.50 0.53Yes 34 19 15
PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR, negative likelihood ratio.
JOURNAL OF HEPATOLOGYReply to: From the CUPIC study: Great times are not coming (?)To the Editor:
Carvalho-Filho and colleagues raised two comments regarding
our paper [1].
The ﬁrst comment relates to the fact that the safety interim
analysis may have been underpowered, and that the number of
variables included in the multivariate analysis did not respect
the 10 events per variable ratio (EVR) rule. The second comment
relates to bias induced by potential multicollinearity between
covariates tested in multivariate models. In reply we will address
three points.
(1) Might associations between death or complications with
albumin and platelet count be a ‘false positive result’?
Indeed, the non-respect of the 10 events per variable rule is
mostly known to increase the type I error, i.e., the risk of a
signiﬁcant association when no association truly exists. First,
the relevance of the 10 events per variable rule has been dis-
cussed and further simulation studies showed that, in a logistic
model with two binary predictors such as ours, the inﬂation of
type I error is moderate [2]. Second, and most importantly, the
positive associations with albumin and platelet count were not
exploratory post hoc ﬁndings but were a priori hypothesized asso-
ciations, which limited the risk of false positive results. Third, we
found a clear dose-effect relationship with each of these two
factors when considered as a continuous variable and deaths or
severe complications (Table 1) – this argues for a direct or indi-
rect causality link between albumin or platelet count and severe
outcome.
Therefore, we do believe that independent associations
between albumin and platelet count are real and not the conse-
quence of inﬂated type I error due to low EVR.
(2) Might odds-ratios estimates be biased given the low num-
ber of events and potential multicollinearity?
First, we performed backward logistic models, and thus, the
ﬁnal model (with an event per variable ratio of 15) did not
include any other predictor than albumin and platelet count,
which limited the bias in estimating the strengths of association
and avoided any collinearity problem in ﬁnal model estimates.
Second, we also performed additional analyses using 1000 boot-
strap samples to derive bias-corrected conﬁdence intervals. The
bootstrap estimates of conﬁdence intervals were (3.27–15.6) for
albumin <35 g/L, and (1.43–7.85) for platelet count 6100 
109/L, conﬁrming our ﬁgures.
Therefore we do believe that our estimates are robust and
were not affected by our analytic strategy.
(3) Might there be any other missed predictor of the risk of
death or complications?
Of course, we cannot exclude that our study may have been
underpowered to detect other potential associations. However,Journal of Hepatology 2014 vol. 60 j 229–236 235
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Table 1. Dose-effect relationship between albumin or platelets and deaths
and/or severe complications.
Platelet count 
(in 109/L)
Complications 
or death (n (%))
Albumin 
(in g/L)
Complications 
or death (n (%))
≤50 3 (25) ≤32 9 (32)
51-80 8 (16) 33-34 8 (27)
81-100 8 (16) 35-36 3 (9)
101-120 7 (11) 37-38 2 (4)
121-150 4 (4) 39-40 3 (4)
>150 2 (1) >40 5 (2)
Letters to the Editoras Carvahlo et al. pointed out from our results, the negative
predictive values of the two factors were high. The C-statistic –
a measure of the predictive accuracy corresponding to the area
under the ROC curve of the logistic model including albumin
and platelet count was 0.75 which is considered ‘‘acceptable
discrimination’’ [3] and the Hosmer-Lemeshow’s goodness of ﬁt
test indicated a correct ﬁt (p value = 0.15, should be >0.05). While
we agree that our ﬁndings should be validated in other HCV
patients with cirrhosis, we do conﬁrm that these two simple
factors can be used to evaluate the risk of severe outcome in
patients who start triple HCV therapy.
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